Sm p80
Alternative Names: SchistoShield; Sm-p80Latest Information Update: 28 Jun 2025
At a glance
- Originator Texas Tech University Health Sciences Center
- Developer National Institute of Allergy and Infectious Diseases; PAI Life Sciences
- Class Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Schistosomiasis
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Schistosomiasis(Prevention) in Burkina Faso (IM, Injection)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Schistosomiasis(Prevention) in Madagascar (IM, Injection)
- 28 Mar 2025 No recent reports of development identified for phase-I development in Schistosomiasis(Prevention) in USA (IM, Injection)